Stem Cells and Cancer Stem Cells,Volume 3 pp 179-187

Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 3) | Cite as

Mesenchymal Stem Cells For Cellular Therapies

  • Catarina Madeira
  • Francisco dos Santos
  • Pedro Z. Andrade
  • Cláudia Lobato da Silva
  • Joaquim M.S. Cabral
Chapter

Abstract

In the last decade, an increasing number of studies led to a more in-depth knowledge of the immunomodulatory, engraftment-promoting and regenerative properties of mesenchymal stem cells (MSC). Research on MSC clinical applications has been intensified in the last few years and, as a consequence, in early 2011 there were already 165 registered clinical trials with MSC. On the other hand, some relevant pre-clinical studies have shown promising results in terms of efficiency and safety when using MSC overexpressing therapeutic proteins. Although the merging of both gene and stem cell therapy still remain in a pre-clinical stage, in few years this innovative therapy will certainly be exploited in clinical trials and ultimately established as current medical practice. Indeed, the extraordinary features of MSC has widen the number of MSC based clinical therapies, eventually anticipating palliative procedures instead of current aggressive therapies, or even the cure of untreatable diseases.

Keywords

Graft versus host disease GSK-3β DNA FDA EMA VEGF 

References

  1. Alfaro MP, Vincent A, Saraswati S, Thorne CA, Hong CC, Lee E, Young PP (2010) SFRP2 suppression of bone morphogenic protein (BMP) and wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 285:35645–35653PubMedCrossRefGoogle Scholar
  2. Almeida-Porada G, Brown RL, Mackintosh FR, Zanjani ED (2000) Evaluation of serum-free culture conditions able to support the ex vivo expansion and engraftment of human hematopoietic stem cells in the human-to-sheep xenograft model. J Hematol Stem Cell Res 9:683–693CrossRefGoogle Scholar
  3. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE (2007) Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110:2764–2767PubMedCrossRefGoogle Scholar
  4. Buja LM, Vela D (2010) Immunologic and inflammatory reactions to exogenous stem cells implications for experimental studies and clinical trials for myocardial repair. J Am Coll Cardiol 56:1693–1700PubMedCrossRefGoogle Scholar
  5. Caplan AI (2009) Why are MSCs therapeutic? New data: new insight. J Pathol 217:318–324PubMedCrossRefGoogle Scholar
  6. Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH, Cho KG, Paek SH, Lee YD, Kim SS, Suh-Kim H (2010) The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 127:1975–1983PubMedCrossRefGoogle Scholar
  7. Chen SL, Fang W, Ye F, Liu YH, Qian J, Shan S, Zhang J, Zhao RCH, Liao LM, Lin S, Sun JP (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94:92–95PubMedCrossRefGoogle Scholar
  8. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG, Kong D (2008) Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16:571–579PubMedCrossRefGoogle Scholar
  9. Cho J, Zhai P, Maejima Y, Sadoshima J (2011) Myocardial injection with GSK-3 beta-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res 108:478–489PubMedCrossRefGoogle Scholar
  10. Da Silva CL, Goncalves R, Crapnell KB, Cabral JMS, Zanjani ED, Almeida-Porada G (2005) A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells. Exp Hematol 33:828–835PubMedCrossRefGoogle Scholar
  11. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8:315–317PubMedCrossRefGoogle Scholar
  12. Dos Santos F, Andrade PZ, Boura JS, Abecasis MM, Da Silva CL, Cabral JMS (2010) Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. J Cell Physiol 223:27–35PubMedGoogle Scholar
  13. Duijvestein M, Vos ACW, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EMC, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, Van Den Brink GR, Hommes DW (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal crohn’s disease: results of a phase I study. Gut 59:1662–1669PubMedCrossRefGoogle Scholar
  14. Eibes G, Dos Santos F, Andrade PZ, Boura JS, Abecasis MMA, Da Silva CL, Cabral JMS (2010) Maximizing the ex vivo expansion of human mesenchymal stem cells using a microcarrier-based stirred culture system. J Biotechnol 146:194–197PubMedCrossRefGoogle Scholar
  15. Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang WW, Klopsch C, Ong LL, Li WZ, Ma N, Steinhoff G (2011) Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS One 6:e15652PubMedCrossRefGoogle Scholar
  16. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA (2005) A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416–1423PubMedCrossRefGoogle Scholar
  17. Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, Mazzanti B, Dal Pozzo S, Milia AF, Bellando-Randone S, Miniati I, Fiori G, Fontana R, Amanzi L, Braschi F, Bosi A, Matucci-Cerinic M (2010) Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis a case report. Ann Int Med 153:650–654PubMedGoogle Scholar
  18. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, Demaria AN, Denktas AE, Gammon RS, Hermiller JB Jr., Reisman MA, Schaer GL, Sherman W (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277–2286PubMedCrossRefGoogle Scholar
  19. Huang J, Zhang ZP, Guo JA, Ni AG, Deb A, Zhang LN, Mirotsou M, Pratt RE, Dzau VJ (2010) Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 106:1753–1762PubMedCrossRefGoogle Scholar
  20. Kim SH, Moon HH, Kim HA, Hwang KC, Lee M, Choi D (2010) Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther 19:741–750CrossRefGoogle Scholar
  21. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441PubMedCrossRefGoogle Scholar
  22. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586PubMedCrossRefGoogle Scholar
  23. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ (2009) Intravenous hmscs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein tsg-6. Cell Stem Cell 5:54–63PubMedCrossRefGoogle Scholar
  24. Loffredo FS, Steinhauser ML, Gannon J, Lee RT (2011) Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. doi:10.1016/j.stem.2011.02.002Google Scholar
  25. Mintzer MA, Simanek EE (2009) Nonviral vectors for gene delivery. Chem Rev 109:259–302PubMedCrossRefGoogle Scholar
  26. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang LN, Solomon SD, Deb A, Dzau VJ, Pratt RE (2006) Mesenchymal stem cells overexpressing akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 14:840–850PubMedCrossRefGoogle Scholar
  27. Prasad VK, Lucas KG, Kleiner GI, Talano JAM, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J (2011) Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (prochymal (TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17:534–541PubMedCrossRefGoogle Scholar
  28. Ringden O, Keating A (2011) Mesenchymal stromal cells as treatment for chronic GvHD. Bone Marrow Transplant 46:163–164PubMedCrossRefGoogle Scholar
  29. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397PubMedCrossRefGoogle Scholar
  30. Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC (2011) The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. doi:10.1038/gt.2010.170Google Scholar
  31. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M (2008) Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Card Res 77:525–533CrossRefGoogle Scholar
  32. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F (2009) Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4:e4992PubMedCrossRefGoogle Scholar
  33. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, Van Oorschot AAM, Goumans MJ, Strijder C, Sze SK, Choo A, Piek JJ, Doevendans PA, Pasterkamp G, De Kleijn DPV (2011) Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 6:206–214PubMedCrossRefGoogle Scholar
  34. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP (2010) Mesenchymal stem cell as salvage treatment for refractory chronic GvHD. Bone Marrow Transplant 45:1732–1740PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Catarina Madeira
    • 1
  • Francisco dos Santos
    • 1
  • Pedro Z. Andrade
    • 1
  • Cláudia Lobato da Silva
    • 1
  • Joaquim M.S. Cabral
    • 2
  1. 1.Department of BioengineeringInstituto Superior Técnico (IST)LisboaPortugal
  2. 2.Department of BioengineeringInstitute for Biotechnology and Bioengineering (IBB), Centre for Biological and Chemical Engineering, Instituto Superior Técnico, Technical University of LisbonLisboaPortugal

Personalised recommendations